Global New Crown Drug/Vaccine CEO Salary Statistics!

In the third year of the spread of the new crown epidemic, the global epidemic situation is still developing

(Read more: 2021 global pharmaceutical company revenue TOP20 announced! Johnson & Johnson, Pfizer, Roche are among the top three, and BioNTech has grown nearly 40 times )

With the luminous heat of the new crown vaccine/drug last year, the CEOs of these product manufacturers have also received rich rewards-

Note: Due to the impact of exchange rate fluctuations, the statistical data are approximate values

Relying on the new crown business, after divesting the generic drug division Pfizer Upjohn, Pfizer once again secured the throne of the global pharmaceutical company TOP 1 (only the revenue of Johnson & Johnson's pharmaceutical business is counted)

However, the CEO of BioNTech, which is co-developing the new crown vaccine with Pfizer, seems to have some unsatisfactory earnings in 2021, but his salary has been reduced by 3.

It is also worth noting that Moderna, which is also the manufacturer of the mRNA new crown vaccine, saw its CEO’s salary increase by 41% last year, which is also the highest salary increase in the list, reaching $18.

In terms of medical treatment, Johnson & Johnson has two major sectors: pharmaceuticals and devices

AstraZeneca, which also has a new crown vaccine, does not seem to be as bright as other companies with vaccines in the table.

Gilead's remdesivir shed its "people's hope" halo last year, and its CEO Daniel O'Day was paid $19.

Eli Lilly, which launched several new drugs including COVID-19 antibodies last year, is making $21.

Although Roche has not invested much in the prevention/treatment of the new crown, but with its two major businesses of diagnosis and pharmaceuticals, its revenue has performed well under the epidemic

GSK's Emma Walmsley has been controversial since taking office, but her pay rise in 2021 is quite impressive, rising 17% to $108.

Merck, like Pfizer, has a new crown oral drug, which was approved even before Pfizer's Paxlovid, but the follow-up performance of the drug does not seem to be as bright as Paxlovid

Reference: MedTrend Medical Trends "Latest! CEO Salary of Global Pharmaceutical Companies in 2021: Johnson & Johnson Highest, Moderna Raises 41%”